J&J wins FDA approval for TRUFILL system to treat chronic subdural hematoma via middle meningeal artery embolization.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHOENIX -- For ...

Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic ...

Earlier this month, Medtronic said the FDA granted the indication for its Onyx liquid embolic system (LES) in the U.S. Onyx ...

Johnson & Johnson MedTech announced that the FDA has approved an expanded indication for the company’s TruFill n-But ...

A novel combination of surgery and embolization used to treat subdural hematomas, bleeding between the brain and its protective membrane due to trauma, reduces the risk of follow-up surgeries, ...

A novel combination of surgery and embolization used to treat subdural hematomas, bleeding between the brain and its protective membrane due to trauma, reduces the risk of follow-up surgeries, ...

The treatment of a subdural hematoma received a major boost with three new randomized controlled trials all showing large and significant benefits of a new embolization process done as an endovascular ...

Society of NeuroInterventional Surgery says findings emphasize the need to update treatment protocols in the field FAIRFAX, Va. — New research by Society of Neurolnterventional Surgery (SNIS) members ...

New research by Society of Neurolnterventional Surgery (SNIS) members found that adjunctive middle meningeal artery embolization (MMAE) for the treatment of chronic subdural hematoma (CSDH) resulted ...

Irvine: Johnson & Johnson MedTech has announced that the U.S. Food and Drug Administration (FDA) has approved an expanded ...